Research Article
Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece
Table 7
Response to second-line treatment according to the chemotherapy regimen.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease. |